Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

132

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

November 1, 2023

Study Completion Date

September 1, 2026

Conditions

Relapsed Ovarian Cancer

Interventions

DRUG

Fluzoparib+Apatinib

Fluzoparib 100mg bid+ Apatinib 375mg qd

DRUG

Fluzoparib Monotherapy

Fluzoparib 150mg bid

All Listed Sponsors

lead

Xiaohua Wu MD

OTHER

NCT05479487 - Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment | Biotech Hunter | Biotech Hunter